Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 683 results for "clopidogrel"

TRANSLATE-ACS: No MACE Benefit With Prasugrel in ACS

WASHINGTON, DC — A real-world comparison of clopidogrel vs prasugrel (Effient, Lilly/Daiichi-Sankyo) in nearly 12 000 acute coronary syndrome (ACS) patients undergoing PCI revealed no significant differences in the rate of major adverse ... American Journal of Public Health, 9 hours ago

1 images for "clopidogrel"

Journal of Clinical Pharmacology, 2 months ago

Ticagrelor vs Clopidogrel in Non-ST-Elevation ACS

Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S ...
 General Medicine eJournal1 week ago

Human medicines European public assessment report (EPAR): Clopidogrel Qualimed, clopidogrel, Revision: 4, Withdrawn

Clopidogrel Qualimed : EPAR - Product Information SV = svenska 2009-10-14 2014-09-08 Clopidogrel Qualimed ...
 European Medicines Agency1 week ago
CBS News

Advancement of Ascendia Pharmaceutical's Nano-Emulsion Technology Platform with Its Lead Development Program ASD-002

There is a significant unmet medical need for a parenteral clopidogrel dosage form for the treatment of Acute Coronary Syndrome under life-threatening situations, said Jingjun Jim Huang, Ph.D ., CEO of Ascendia. With our ...
 Morningstar.com2 weeks ago Ascendia Applies Nano-Emulsion Technology to Injectable Blood Thinner Medicine  Azonano1 week ago Advancement of Ascendia's nano-emulsion technology platform with Its lead development program ASD-002  Pharmaceutical Business Review1 week ago US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA  4 Traders3 weeks ago

New and Generic Drug Approvals: Clopidogrel

Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to
 U.S. Food and Drug Administration2 days ago

Vorapaxar with or without clopidogrel after nonST-segment elevation acute coronary syndromes: Results from the TRACER trial - Accepted Manuscript

European Online Customer Service The Boulevard Langford Lane, Kidlington Oxford. OX5 1GB UK Hours: Monday - Friday, 8:30am - 5:00pm (Greenwich Mean Time/British Summer Time) Tel: +44 (0) 1865-843177 (Within Europe) Fax: +44 (0) ...
 American Heart Journal2 days ago Impact of Diabetes Mellitus and Metabolic Syndrome on Acute and Chronic On-Clopidogrel Platelet Reactivity in Patients With Stable Coronary Artery Disease Undergoing Drug-Eluting Stent Placement - Accepted Manuscript  American Heart Journal2 days ago Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel? - Corrected Proof  American Heart Journal1 month ago

Stent Thrombosis After MI Is Higher With Clopidogrel Than Prasugrel in in Real World Setting: Presented at TCT

You currently are not registered for any FirstWord Pharma services. Register to FirstWord Pharma for free access to 10 articles every 30 days: You can also: Wait 3 days for your content allowance to be renewed. Sign up for a free trial to ...
 FirstWord Pharma2 days ago

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following___

 TCTMD.com3 days ago Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention A Contemporary Review  Journal of the American College of Cardiology3 days ago TCT.14: Six-week triple therapy fails to unseat six-month duration  Cardiovascular Business3 days ago
MedPage Today

TCT-502 Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

Note: Since your browser does not support Javascript, you must press the Continue button once
 Journal of the American College of Cardiology1 week ago TCT-492 Stent Thrombosis With Ticagrelor Versus Clopidogrel After Percutaneous Coronary Intervention and Ticagrelor or Clopidogrel in Patients With Acute Coronary Syndromes in a Real World Setting  Journal of the American College of Cardiology1 week ago TCT-480 Prior Clopidogrel Therapy in Patients Presenting with Acute Coronary Syndromes (ACS) is Associated with Increase Risk of Stent Thrombosis  Journal of the American College of Cardiology1 week ago TCT-499 Comparable outcomes on single use of clopidogrel vs. dual antiplatelet therapy after coronary stenting in patients with acute myocardial infarction  Journal of the American College of Cardiology1 week ago

TCT-500 Prasugrel Is A More Potent Platelet Inhibitor Than Clopidogrel In Bivalirudin-Treated Patients. Comparative Effects of Two Thienopyridines On ADP And Thrombin Receptor Antagonism As Assessed By Aggregometry

Note: Since your browser does not support Javascript, you must press the Continue button once
 Journal of the American College of Cardiology1 week ago TCT-494 Safety and Effectiveness of Prasugrel vs. Clopidogrel in the Setting of Bivalirudin vs. Heparin Use: 30-day Results from TRANSLATE-ACS  Journal of the American College of Cardiology1 week ago In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights Into Contemporary Practice From the National Cardiovascular Data Registry [Pharmacology]  Circulation: Cardiovascular Interventions4 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less